P160 the First Phase 2A Proof-Of-Concept Study of a Selective NLRP3 Inflammasome Inhibitor, Dapansutrile™ (OLT1177™), in Acute Gout

doi 10.1136/annrheumdis-2018-ewrr2019.142
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ Publishing Group Ltd and European League Against Rheumatism


Related search